Supplementary Appendix 8: Bootstrapping differences in SARS-CoV-2 anti-spike and anti-RBD relative ratios following BNT162b2 or mRNA-1273 vaccination at 6-7 weeks and 12 weeks after second dose

		No. of patients		Relative ratio, (95% CI)		
Antibody	Weeks after second dose	BNT162b2	mRNA-1273	BNT162b2	mRNA-1273	Difference in relative ratio, median (95% CI)
Anti-spike	6-7 weeks	70	87	1.58 (1.47-1.61)	1.72 (1.71-1.76)	0.14 (0.10-0.24)
	12 weeks	122	71	1.45 (1.36-1.51)	1.93 (1.88-1.97)	0.47(0.39-0.57)
Anti-RBD	6-7 weeks	70	87	1.23 (0.97-1.39)	1.44 (1.37-1.48)	0.21 (0.00-0.48)
	12 weeks	122	71	0.89 (0.75-1.11)	1.32 (1.26-1.38)	0.43 (0.15-0.58)

Note: CI=confidence interval, RBD=receptor binding domain.

Note: Bootstrapping (random case sampling with replacement with 5000 replications) was used to generate 95% confidence intervals for the median difference in anti-spike and anti-RBD levels (mRNA-1273 minus BNT162b2) relative ratios at both 6-7 and 12 weeks.

Appendix 8, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.